New hope for hard-to-treat stomach cancer: targeted combo enters phase 2 trial
NCT ID NCT06947291
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 24 times
Summary
This study tests a new drug (glumetinib) combined with chemotherapy for people with advanced stomach cancer or related tumors that have a specific gene change (MET overexpression or amplification). The goal is to see if the combination is safe and can shrink tumors. About 350 adults will take part in this phase 2 trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED GASTRIC CANCER/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AND OTHER SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhejiang Cancer Hospital
RECRUITINGHangzhou, Zhejiang, China
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.